Remote sensing of directional wave spectra using the surface contour radar

A unique radio-oceanographic remote sensing instrument was developed. The 36 GHz airborne Surface Contour Radar (SCR) remotely produces a real-time topographical map of the sea surface beneath the aircraft. It can routinely produce ocean directional wave spectra with off-line data processing. The transmitter is a coherent dual-frequency device that uses pulse compression to compensate for the limited available power at Ka band. The radar has selectable pulse widths of 1, 2, 4, and 10 nanoseconds. The transmitting antenna is a 58 lambda horn fed dielectric lens whose axis is parallel to the longitudinal axis of the aircraft. It illuminates an elliptical mirror which is oriented 45 deg to the lens' longitudinal axis to deflect the beam towards the region beneath the aircraft. The mirror is oscillated in a sinusoidal fashion through mechanical linkages driven to a variable speed motor to scan the transmitter beam (1.2 deg X 1.2 deg) with + or - 16 deg of the perpendicular to the aircraft wings in the plane perpendicular to the aircraft flight direction

Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma

The purpose of this study was to identify novel areas of genomic copy number change associated with transformation from follicular lymphoma (FL) to diffuse large B cell lymphoma (DLBL). DNA was extracted from tumour cells micro-dissected from paraffin- embedded tissue sections in 24 patients with FL and subsequent transformation to DLBL and 18 patients with de novo DLBL. Tumour DNA was compared to reference DNA using comparative genomic hybridization. Abnormalities common to all 3 groups were gains on chromosomes 4q, 5q, 7q, 11q and X and losses on 3p, 8p and 10q. Copy number changes seen in both transformed and de novo DLBL and not seen in FL were gains on 2p and losses on 1q, 15q and Xq. Gains on 2q, 6p, 7p and 17q and losses on 5p and 8q were specific to transformed DLBL cases. Gain on 12q12-14 was found in 52% of the transformed DLBL cases and was never seen in its follicular counterpart. Patterns of genomic copy number change associated with specific clinical events in NHL have been demonstrated and suggest that gains on 2q, 6p, 7p, 12q and 17q and losses on 5p and 8q may be important in the transformation from low to high-grade disease. © 2001 Cancer Research Campaign http://www.bjcancer.co

The Politics of Commerce : The Congress of Chambers of Commerce of the Empire, 1886-1914

Peer reviewedPublisher PD

A Candidate Protoplanet in the Taurus Star Forming Region

HST/NICMOS images of the class I protostar TMR-1 (IRAS04361+2547) reveal a faint companion with 10.0" = 1400 AU projected separation. The central protostar is itself resolved as a close binary with 0.31" = 42 AU separation, surrounded by circumstellar reflection nebulosity. A long narrow filament seems to connect the protobinary to the faint companion TMR-1C, suggesting a physical association. If the sources are physically related then we hypothesize that TMR-1C has been ejected by the protobinary. If TMR-1C has the same age and distance as the protobinary then current models indicate its flux is consistent with a young giant planet of several Jovian masses.Comment: 16 pages, 1 figure, Accepted by Astrophysical Journal Letters, Related information is available at http://www.extrasolar.co

Placental site trophoblastic tumour: a rare but potentially curable cancer

Placental site trophoblastic tumour (PSTT) is a rare form of gestational trophoblastic disease (GTD). We have conducted an analysis of all cases of PSTT managed at the Trophoblastic Disease Screening and Treatment Centre, Sheffield, from 1984 to 1996. During this time we received 4988 registrations for GTD and managed seven cases of PSTT. A large range of interval between antecedent pregnancy and presentation was observed – the most common presenting symptoms being irregular vaginal bleeding with or without preceding amenorrhoea. Three out of seven patients had disease confined to the uterus at diagnosis and were successfully treated by hysterectomy alone. Two out of seven patients had pulmonary metastases in addition to uterine tumour and were treated with combination chemotherapy – both are alive and well. Of the remaining two patients one had distant and the other loco-regional metastases and both died despite numerous therapeutic interventions. © 2000 Cancer Research Campaig

Presynaptic Type III Neuregulin1-ErbB signaling targets α7 nicotinic acetylcholine receptors to axons

Type III Neuregulin1 (Nrg1) isoforms are membrane-tethered proteins capable of participating in bidirectional juxtacrine signaling. Neuronal nicotinic acetylcholine receptors (nAChRs), which can modulate the release of a rich array of neurotransmitters, are differentially targeted to presynaptic sites. We demonstrate that Type III Nrg1 back signaling regulates the surface expression of α7 nAChRs along axons of sensory neurons. Stimulation of Type III Nrg1 back signaling induces an increase in axonal surface α7 nAChRs, which results from a redistribution of preexisting intracellular pools of α7 rather than from increased protein synthesis. We also demonstrate that Type III Nrg1 back signaling activates a phosphatidylinositol 3-kinase signaling pathway and that activation of this pathway is required for the insertion of preexisting α7 nAChRs into the axonal plasma membrane. These findings, in conjunction with prior results establishing that Type III Nrg1 back signaling controls gene transcription, demonstrate that Type III Nrg1 back signaling can regulate both short-and long-term changes in neuronal function

Determinants on lens spaces and cyclotomic units

The Laplacian functional determinants for conformal scalars and coexact one-forms are evaluated in closed form on inhomogeneous lens spaces of certain orders, including all odd primes when the essential part of the expression is given, formally as a cyclotomic unitComment: 18 pages, 1 figur

Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate

The Sheffield Trophoblastic Disease Centre treats about 25 patients with persistent trophoblastic disease each year. A total of 75% of patients are classified as low risk according to the Charing Cross Hospital prognostic scoring system and receive methotrexate (MTX) 50 mg, i.m., on days 1, 3, 5, 7 with folinic acid 7.5 mg orally 24 h after each methotrexate injection. There is a 7-day rest between treatment cycles. Remission is achieved in 85% of cases. Approximately 20% of patients experienced pleuritic chest pain and dyspnoea. We have evaluated prospectively lung function in 16 low-risk patients receiving methotrexate. All patients had pulmonary function tests [spirometry-forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), and transfer factor - TLCO, kCO] performed before and after completed treatment. A mean of 7.5 cycles of MTX were administered (range 4-11). There was a significant reduction in the mean TLCO (mean pre/post 8.15/7.38 mmol min-1 kPa-1, P = 0.01), but there were no other statistically significant changes. Three patients experienced respiratory symptoms and were found to have a 39%, 28%, and 11% reduction in TLCO from baseline, improving on follow up to pretreatment levels. Low-dose MTX is an effective therapy but may cause troublesome pulmonary toxicity